Goodwin advised Carrick Therapeutics Ltd, a unique new venture in cancer treatment, in its launch and $95 million funding round. Carrick brings together world-class cancer researchers and drug development experts, backed by premier providers of early stage capital, with the aim of building Europe's leading oncology company. The $95 million funding round was led by ARCH Venture Partners and Woodford Investment Management with participation from Cambridge Enterprise Seed Funds, Cambridge Innovation Capital, Evotec AG, GV (Google Ventures), and Lightstone Ventures.
Carrick Therapeutics is pioneering a portfolio of unique first-in-class cancer treatments that target driver mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient's tumor. Carrick has an ambitious patient-focused vision to serve cancer patients around the world by the introduction of ground-breaking cancer therapies that will transform the way cancer is treated.
The Goodwin team advising Carrick was led by partner Gregg Katz.
For more information on Carrick, please view the press release.